Best Buy Can’t Predict ‘Likelihood or Impact’ of Proposed List 4 Tariffs, Says 10-Q
Best Buy is “actively addressing the risks" of increases to tariffs on Chinese imports, it said in an SEC 10-Q Friday for fiscal Q1 ended May 4. “We have been able to minimize the impact on our business” from the…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
List 3 tariffs “by accelerating purchases and working with our vendors,” it said. The company expects the Trump administration “to continue to seek input into potential further tariff developments,” including the proposed List 4 tariffs on all Chinese imports not previously dutied: “We intend to remain fully engaged in this process. We are also looking into a range of mitigation actions. While our outlook for fiscal 2020 includes the impact of List 3 tariffs increasing from 10% to 25%, we cannot predict, at this stage, the likelihood or impact of further expansion of tariffs to other products we sell or potential new tariffs.” Best Buy paid $125 million for health services company Critical Signal Technologies, completing it May 9, said the retailer. Best Buy disclosed the purchase as part of its connected-health strategy on its May 23 earnings call, but didn't discuss the terms (see 1905230038 or 1905230019).